Investors.com Stock Market Analysis MYGN 03/06/09

Myriad is a midcap. It trades about 871,000 shares a day.
It hails from the Medical-Genetics group, ranked No. 5 among IBD's 197 groups.
The company has logged outstanding earnings growth in the past three quarters, following a string of quarterly and yearly losses.
Sales have grown at an excellent rate in each of the past eight quarters.
Analysts expect earnings to grow 93% in 2009 and 69% in 2010.

Category:

Education

Tags:

• stocks
• trend analysis
• research
• stock market